Core Laboratories (CLB) EPS (Weighted Average and Diluted) (2022 - 2026)

Core Laboratories has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.02 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.02; the trailing twelve-month figure through Mar 2026 stood at $0.64 (up 10.34% YoY), and the FY2025 full-year result was $0.65, down 1.52% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.02, down from $0.13 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $0.48 in Q2 2023, with the low at -$0.02 in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.17 across 5 years, with a median of $0.15 in 2022.
• Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) tumbled 73.33% — and 2024, when it surged 250.0%.
• Core Laboratories' EPS (Weighted Average and Diluted) stood at $0.15 in 2022, then plunged by 73.33% to $0.04 in 2023, then surged by 250.0% to $0.14 in 2024, then decreased by 7.14% to $0.13 in 2025, then tumbled by 115.38% to -$0.02 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.02 (Q1 2026), $0.13 (Q4 2025), and $0.3 (Q3 2025), per Business Quant data.